Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 12/20 | 0.55 |
| ▸ | DRD2 known ✓ | P14416 | 10/20 | 0.54 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.54 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.54 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.54 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.54 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.54 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.54 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.54 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.54 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.54 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.54 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.54 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.54 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.54 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.54 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.54 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.54 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.54 |
| ▸ | HTR7 | P34969 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5766407 | 0.95 | HTR2A (0.59) | HTR2ADRD2HTR7HTR6KCNH2 | |
| SCHEMBL6748047 | 0.86 | HTR2A (0.61) | HTR2ADRD2HTR7HTR6KCNH2 | |
| SCHEMBL6751052 | 0.85 | HTR2A (0.53) | HTR2ADRD2HTR7HTR6KCNH2 | |
| Hydrochloric Acid SCHEMBL6219187 | 0.85 | HTR2A (0.60) | HTR2ADRD2HTR7HTR6KCNH2 | |
| SCHEMBL6188860 | 0.84 | HTR2A (0.70) | HTR2ADRD2HTR7HTR6KCNH2 | |
| SCHEMBL5766916 | 0.82 | HTR2A (0.73) | HTR2ADRD2HTR7HTR6KCNH2 | |
| SCHEMBL9369746 | 0.81 | HTR2A (0.75) | HTR2ADRD2HTR7HTR6KCNH2 | |
| SCHEMBL6751044 | 0.81 | HTR1A (0.61) | HTR2ADRD2HTR7HTR6KCNH2 | |
| SCHEMBL6184766 | 0.81 | HTR2A (0.75) | HTR2ADRD2HTR7HTR6KCNH2 | |
| SCHEMBL6219278 | 0.81 | HTR2A (0.49) | HTR2ADRD2HTR7HTR6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546143-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2005-06-29 | — | — | EP | claimed |
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | ANDREANA TONJA LYNN (US) | 2004-07-15 | — | — | US | claimed |
| WO-2004026864-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-01 | — | — | WO | claimed |
| EP-1546143-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | ANDREANA TONJA LYNN (US) | 2004-07-15 | — | — | US | disclosed |
| WO-2004026864-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | CNR1, DRD2, CNR2 | HTR2A 16/4885DRD2 2/4885HTR1A 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.